Ozempic (semaglutide) is an injectable medication initially designed to manage type 2 diabetes. Over the past few years, its potential to aid weight loss has captured more public attention.

Semaglutide is a drug used for weight loss. Oral tablets and injections are both effective ways to take semaglutide. Oral tablets do not require the use of needles, but you may need to take them ...

The FBI says counterfeit versions of the drugs can cause health issues. The FBI is warning the public about counterfeit compounded weight loss drugs on the market that claim to contain semaglutide ...

Studies show promising results for semaglutide as a potential treatment for alcohol use disorder. Semaglutide, a GLP-1 drug, was initially used for type 2 diabetes treatment and weight loss.

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022. The FDA's announcement comes months after drugmaker Novo Nordisk told the agency ...

What Happens If I Use Expired Semaglutide? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the type 2 diabetes and weight loss medication sold under the brand ...

Semaglutide is the active ingredient in certain brand-name medications prescribed for obesity, type 2 diabetes, and more. Semaglutide belongs to the glucagon-like peptide-1 (GLP-1) receptor ...

We will focus on telehealth companies, like Jack & Jill, that offer Ozempic alternatives over the counter, such as compounded semaglutide and tirzepatide, as well as top FDA-approved weight loss ...

On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 (GLP-1) medication, marking the shortage as ...

Wegovy and Ozempic, both known chemically as semaglutide, were in shortage in the U.S. for much of last year. More on semaglutide compounds: Shortage of popular drugs Wegovy and Ozempic is ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Semaglutide was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in adults with type 2 ...